Sponsors (23)
The bill would greatly expand U.S. support for global TB diagnosis, prevention, surveillance, and R&D—potentially reducing TB burden and strengthening pandemic preparedness—but does so at increased federal cost and administrative/implementation risk for partner countries and implementers.
People in high‑TB‑burden countries (especially patients with chronic TB) will get expanded diagnosis and treatment access through U.S.-backed targets to diagnose and treat 90% of TB cases by 2030.
Low‑income people and other at‑risk populations in partner countries will receive preventive TB treatment at scale (commitment to provide preventive treatment to 30 million people during 2027–2030), lowering future TB incidence.
State and local health systems and partner governments benefit from stronger global public‑health capacity and surveillance because the bill funds epidemiological monitoring and integration with health systems, improving pandemic preparedness and early detection.
U.S. taxpayers may face increased federal expenditures to expand foreign assistance and TB programs through 2032, raising government spending obligations.
Ambitious numeric targets (e.g., 80% incidence reduction, 90% mortality reduction) may be unrealistic for partner countries and could strain implementation resources, risking unmet goals and wasted effort.
Emphasis on procurement of drugs and diagnostics could expose U.S. programs and beneficiaries to higher pharmaceutical procurement costs and supply‑chain complexities without guaranteed price controls or savings.
Based on analysis of 2 sections of legislative text.
Creates a statutory U.S. foreign assistance framework to prevent, diagnose, treat, and eliminate TB worldwide and sets 2027–2030 numeric targets, reporting, and oversight.
Official title: To prevent, treat, and cure tuberculosis globally.
Introduced September 2, 2026 by Ami Bera · Last progress September 2, 2026
Directs U.S. foreign assistance to prevent, diagnose, treat, control, and eliminate tuberculosis (including drug-resistant TB) by creating a statutory framework for programs, research, procurement, and integration with partner country health systems. Requires the President to set numerical global TB goals for 2027–2030, mandates annual reporting and a Comptroller General evaluation, and sunsets the authority on January 1, 2033. Establishes specific targets (e.g., large reductions in incidence and mortality versus 2015, high diagnosis and treatment success rates, and preventive treatment for 30 million people), requires program strengthening and R&D reporting, and directs U.S. agencies to prioritize TB-related assistance and coordination with global health partners.